Circulating/VBG
Tumor/NN
DNA/NN
in/IN
a/DT
Breast/NN
Cancer/NN
Patient/JJ
's/POS
Plasma/NN
Represents/NNS
Driver/NN
Alterations/NNS
in/IN
the/DT
Tumor/NN
Tissue/NN
./.
====================
Tumor/NN
tissues/NNS
from/IN
biopsies/NNS
or/CC
surgery/NN
are/VBP
major/JJ
sources/NNS
for/IN
the/DT
next/JJ
generation/NN
sequencing/NN
(/(
NGS/NN
)/)
study/NN
,/,
but/CC
these/DT
procedures/NNS
are/VBP
invasive/JJ
and/CC
have/VBP
limitation/NN
to/TO
overcome/VB
intratumor/NN
heterogeneity/NN
./.
====================
Recent/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
driver/VBP
alterations/NNS
in/IN
tumor/NN
tissues/NNS
can/MD
be/VB
detected/VBN
by/IN
liquid/JJ
biopsy/NN
which/WDT
is/VBZ
a/DT
less/RBR
invasive/JJ
technique/NN
capable/JJ
of/IN
both/DT
capturing/JJ
the/DT
tumor/NN
heterogeneity/NN
and/CC
overcoming/VBG
the/DT
difficulty/NN
in/IN
tissue/NN
sampling/NN
./.
====================
However/RB
,/,
it/PRP
is/VBZ
still/RB
unclear/JJ
whether/IN
the/DT
driver/RB
alterations/NNS
in/IN
liquid/JJ
biopsy/NN
can/MD
be/VB
detected/VBN
by/IN
targeted/VBN
NGS/NN
and/CC
how/WRB
those/DT
related/JJ
to/TO
the/DT
tissue/NN
biopsy/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
performed/VBD
whole-exome/DT
sequencing/NN
for/IN
a/DT
breast/NN
cancer/NN
tissue/NN
and/CC
identified/VBD
PTEN/NN
p.H259fs*7/NN
frameshift/NN
mutation/NN
./.
====================
In/IN
the/DT
plasma/NN
DNA/NN
(/(
liquid/JJ
biopsy/NN
)/)
analysis/NN
by/IN
targeted/VBN
NGS/NN
,/,
the/DT
same/JJ
variant/JJ
initially/RB
identified/VBN
in/IN
the/DT
tumor/NN
tissue/NN
was/VBD
also/RB
detected/VBN
with/IN
low/JJ
variant/JJ
allele/NN
frequency/NN
./.
====================
This/DT
mutation/NN
was/VBD
subsequently/RB
validated/VBN
by/IN
digital/JJ
polymerase/NN
chain/NN
reaction/NN
in/IN
liquid/JJ
biopsy/NN
./.
====================
Our/PRP$
result/NN
confirm/VBP
that/IN
driver/VBP
alterations/NNS
identified/VBD
in/IN
the/DT
tumor/NN
tissue/NN
were/VBD
detected/VBN
in/IN
liquid/JJ
biopsy/NN
by/IN
targeted/VBN
NGS/NN
as/IN
well/RB
,/,
and/CC
suggest/VBP
that/IN
a/DT
higher/JJR
depth/NN
of/IN
sequencing/NN
coverage/NN
is/VBZ
needed/VBN
for/IN
detection/NN
of/IN
genomic/JJ
alterations/NNS
in/IN
a/DT
liquid/JJ
biopsy/NN
./.
====================
Next/RB
generation/NN
sequencing/NN
(/(
NGS/NN
)/)
technology/NN
has/VBZ
not/RB
only/RB
revolutionized/VBD
cancer/NN
research/NN
but/CC
also/RB
is/VBZ
currently/RB
being/VBG
used/VBN
to/TO
guide/NN
clinicians/NNS
'/``
decision-making/VBG
for/IN
cancer/NN
treatments/NNS
./.
====================
Although/IN
tumor/NN
tissues/NNS
from/IN
biopsies/NNS
or/CC
surgery/NN
are/VBP
major/JJ
sources/NNS
for/IN
the/DT
NGS/NN
study/NN
of/IN
primary/JJ
,/,
metastatic/JJ
and/CC
resistant/JJ
tumors/NNS
,/,
these/DT
serial/JJ
tumor/NN
biopsies/NNS
are/VBP
often/RB
invasive/JJ
procedures/NNS
limited/JJ
to/TO
certain/JJ
locations/NNS
and/CC
not/RB
easily/RB
acceptable/JJ
in/IN
the/DT
clinic/JJ
./.
====================
More/RBR
importantly/RB
,/,
tissue/NN
biopsy/NN
has/VBZ
a/DT
severe/JJ
limitation/NN
in/IN
view/NN
of/IN
the/DT
pronounced/JJ
genomic/JJ
and/CC
phenotypic/JJ
heterogeneity/NN
of/IN
the/DT
tumor/NN
tissues/NNS
[/(
1/CD
]/)
./.
====================
To/TO
overcome/VB
the/DT
limitations/NNS
of/IN
tissue/NN
biopsies/NNS
or/CC
surgery/NN
,/,
a/DT
less/RBR
invasive/JJ
technique/NN
capable/JJ
of/IN
both/DT
capturing/JJ
the/DT
tumor/NN
heterogeneity/NN
and/CC
overcoming/VBG
the/DT
difficulty/NN
in/IN
tissue/NN
sampling/NN
during/IN
the/DT
course/NN
of/IN
therapy/NN
is/VBZ
needed/VBN
./.
====================
Circulating/VBG
tumor/NN
DNA/NN
(/(
ctDNA/JJ
)/)
is/VBZ
comprised/VBN
of/IN
small/JJ
fragments/NNS
of/IN
DNA/NN
released/VBN
from/IN
cells/NNS
undergoing/VBG
apoptosis/NN
or/CC
necrosis/NN
in/IN
tumor/NN
tissues/NNS
[/(
2/CD
]/)
./.
====================
Recent/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
driver/VBP
alterations/NNS
in/IN
tumor/NN
tissues/NNS
can/MD
be/VB
detected/VBN
by/IN
liquid/JJ
biopsy/NN
for/IN
ctDNA/JJ
[/(
3/CD
]/)
./.
====================
However/RB
,/,
it/PRP
is/VBZ
still/RB
uncertain/JJ
whether/IN
the/DT
driver/RB
alterations/NNS
in/IN
ctDNA/JJ
can/MD
be/VB
detected/VBN
by/IN
targeted/VBN
NGS/NN
and/CC
how/WRB
those/DT
related/JJ
to/TO
the/DT
tissue/NN
biopsy/NN
./.
====================
A/DT
56-year/JJ
old/JJ
woman/NN
was/VBD
referred/VBN
to/TO
the/DT
oncology/NN
department/JJ
for/IN
evaluation/NN
of/IN
her/RB
right/JJ
shoulder/JJR
pain/NN
./.
====================
She/PRP
was/VBD
previously/RB
diagnosed/VBN
as/IN
a/DT
breast/NN
cancer/NN
6/CD
years/NNS
ago/NN
./.
====================
The/DT
patient/NN
was/VBD
treated/VBN
with/IN
quadrantectomy/RB
along/IN
with/IN
axillary/JJ
node/NN
dissection/NN
(/(
invasive/JJ
ductal/JJ
carcinoma/NN
,/,
pT2N0M0/RB
,/,
estrogen/NN
receptor/NN
[/(
ER/NN
]/)
positive/JJ
,/,
progesterone/NN
receptor/NN
positive/JJ
and/CC
human/JJ
epidermal/JJ
growth/NN
factor/NN
receptor/NN
2/CD
[/(
HER2/NN
]/)
negative/JJ
)/)
,/,
adjuvant/JJ
radiation/NN
of/IN
the/DT
left/NN
breast/NN
,/,
and/CC
adjuvant/JJ
toremifen/NN
(/(
an/DT
oral/JJ
selective/JJ
ER/NN
modulator/NN
)/)
for/IN
5/CD
years/NNS
./.
====================
Seven/CD
months/NNS
after/IN
the/DT
termination/NN
of/IN
adjuvant/JJ
toremifen/NN
,/,
the/DT
patient/NN
a/DT
pathologic/JJ
fracture/NN
of/IN
right/JJ
distal/JJ
clavicle/NN
,/,
multiple/JJ
bone/NN
,/,
lung/NN
and/CC
liver/NN
metastases/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
./.
====================
During/IN
3/CD
years/NNS
of/IN
the/DT
systemic/JJ
treatment/NN
,/,
the/DT
patient/NN
had/VBD
progression/NN
of/IN
chest/JJS
,/,
liver/NN
and/CC
bone/NN
metastases/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
2/CD
)/)
./.
====================
To/TO
identify/VB
the/DT
genetic/JJ
alterations/NNS
in/IN
the/DT
tumor/NN
tissue/NN
,/,
we/PRP
performed/VBD
whole-exome/DT
sequencing/NN
(/(
WES/NNS
)/)
for/IN
the/DT
cancer/NN
tissue/NN
metastasized/VBN
to/TO
femur/JJ
along/IN
with/IN
her/RB
matched/VBN
normal/JJ
DNA/NN
form/NN
peripheral/JJ
blood/NN
./.
====================
Generation/NN
and/CC
processing/NN
of/IN
the/DT
sequencing/NN
data/NNS
were/VBD
performed/VBN
as/IN
previously/RB
described/VBN
[/(
4/CD
]/)
./.
====================
In/IN
the/DT
WES/NN
,/,
a/DT
total/JJ
of/IN
53/CD
nonsilent/JJ
somatic/JJ
mutations/NNS
and/CC
23/CD
copy/NN
number/NN
alterations/NNS
(/(
CNAs/NNS
)/)
were/VBD
detected/VBN
(/(
Supplementary/JJ
Tables/NNS
1/CD
and/CC
2/CD
)/)
./.
====================
Among/IN
them/PRP
,/,
PTEN/NN
p.H259fs*7/NN
frameshift/NN
mutation/NN
(/(
Fig/NN
./.
====================
1A/NN
)/)
as/IN
well/RB
as/IN
FGFR1/NN
,/,
c-MYC/NN
,/,
CDK4/NN
,/,
and/CC
MDM2/NN
amplifications/NNS
(/(
Fig/NN
./.
====================
1E/NN
)/)
were/VBD
identified/VBN
as/IN
driver/RB
alterations/NNS
in/IN
this/DT
tumor/NN
./.
====================
To/TO
validate/VB
these/DT
,/,
the/DT
metastatic/JJ
tumor/NN
and/CC
matched/VBN
normal/JJ
samples/NNS
of/IN
the/DT
patient/NN
were/VBD
re-analyzed/VBN
by/IN
a/DT
targeted/VBN
NGS/NN
./.
====================
Targeted/VBN
NGS/NN
was/VBD
performed/VBN
using/VBG
the/DT
OncoChase/NN
Cancer/NN
Panel/NN
v0.9/CD
(/(
ConnectaGen/NN
,/,
Seoul/JJ
,/,
Korea/NN
)/)
consisting/VBG
of/IN
78/CD
well-characterized/JJ
cancer/NN
genes/NNS
(/(
Supplementary/JJ
Table/JJ
3/CD
)/)
with/IN
Ion/NN
PGM/NN
Dx/NN
system/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
,/,
Waltham/NNP
,/,
MA/NN
,/,
USA/NNP
)/)
./.
====================
Coverage/NN
of/IN
depth/NN
was/VBD
416×/CD
for/IN
the/DT
metastatic/JJ
tumor/NN
sample/NN
and/CC
754×/CD
for/IN
the/DT
normal/JJ
sample/JJ
./.
====================
In/IN
the/DT
OncoChase/NN
analysis/NN
,/,
all/DT
five/CD
driver/RB
alterations/NNS
previously/RB
identified/VBN
in/IN
the/DT
WES/NN
were/VBD
consistently/RB
detected/VBN
(/(
Fig/NN
./.
====================
1B/NN
and/CC
1E/NN
)/)
./.
====================
Of/IN
note/NN
,/,
variant/JJ
allele/NN
frequency/NN
(/(
VAF/NN
)/)
of/IN
PTEN/NN
frameshift/NN
mutation/NN
detected/VBN
by/IN
WES/NN
(/(
68.8/CD
%/NN
)/)
were/VBD
almost/RB
similar/JJ
to/TO
that/DT
detected/VBN
by/IN
OncoChase/NN
(/(
63.2/CD
%/NN
)/)
,/,
suggesting/VBG
the/DT
OncoChase/NN
Cancer/NN
Panel/NN
may/MD
be/VB
reliable/JJ
for/IN
the/DT
detection/NN
of/IN
driver/RB
alterations/NNS
./.
====================
Next/RB
,/,
we/PRP
analyzed/VBD
the/DT
plasma/NN
DNA/NN
(/(
liquid/JJ
biopsy/NN
)/)
of/IN
the/DT
patient/NN
using/VBG
the/DT
same/JJ
cancer/NN
panel/NN
(/(
OncoChase/NN
Cancer/NN
Panel/NN
v0.9/CD
)/)
./.
====================
Coverage/NN
of/IN
depth/NN
was/VBD
1,213×/CD
for/IN
the/DT
liquid/JJ
biopsy/NN
sample/NN
./.
====================
The/DT
PTEN/NN
frameshift/NN
mutation/NN
initially/RB
identified/VBN
in/IN
the/DT
tumor/NN
tissue/NN
was/VBD
also/RB
detected/VBN
in/IN
her/RB
liquid/JJ
biopsy/NN
with/IN
a/DT
VAF/NN
of/IN
11.2/CD
%/NN
(/(
Fig/NN
./.
====================
1C/NN
)/)
./.
====================
This/DT
mutation/NN
was/VBD
subsequently/RB
validated/VBN
by/IN
digital/JJ
polymerase/NN
chain/NN
reaction/NN
(/(
Fig/NN
./.
====================
1D/CD
)/)
./.
====================
The/DT
ctDNA/JJ
also/RB
harbored/VBD
c-MYC/NN
,/,
CDK4/NN
and/CC
MDM2/NN
amplification/NN
but/CC
signal/NN
intensities/NNS
of/IN
the/DT
CNAs/NNS
were/VBD
relatively/RB
lower/JJR
than/IN
those/DT
of/IN
the/DT
tissue/NN
biopsy/NN
(/(
Fig/NN
./.
====================
1E/NN
)/)
./.
====================
One/CD
CNA/NN
(/(
FGFR/NN
amplification/NN
)/)
identified/VBD
in/IN
the/DT
tumor/NN
tissue/NN
was/VBD
not/RB
detected/VBN
in/IN
the/DT
ctDNA/JJ
./.
====================
Comprehensive/JJ
review/NN
of/IN
the/DT
hormone/NN
status/NN
(/(
ER/NN
positive/JJ
)/)
and/CC
genetic/JJ
alteration/NN
(/(
CDK4/NN
amplification/NN
)/)
status/NN
strongly/RB
suggested/VBD
the/DT
use/NN
of/IN
CDK4/6/NN
inhibitors/NNS
such/JJ
as/IN
palbociclib/JJ
[/(
5/CD
]/)
combined/JJ
with/IN
aromatase/NN
inhibitor/NN
[/(
6/CD
]/)
./.
====================
However/RB
,/,
due/JJ
to/TO
her/RB
dismal/JJ
hepatic/JJ
function/NN
,/,
palbociclib/NN
was/VBD
not/RB
administered/VBN
,/,
and/CC
she/PRP
passed/VBD
away/NN
after/IN
52/CD
months/NNS
of/IN
cancer/NN
recurrence/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
showed/VBD
an/DT
example/NN
that/DT
driver/VBP
alterations/NNS
identified/VBD
in/IN
the/DT
tumor/NN
tissue/NN
were/VBD
detected/VBN
in/IN
liquid/JJ
biopsy/NN
by/IN
targeted/VBN
NGS/NN
as/IN
well/RB
./.
====================
The/DT
low/JJ
VAF/NN
of/IN
mutation/NN
and/CC
attenuated/VBD
CNA/NN
signals/NNS
in/IN
the/DT
liquid/JJ
biopsy/NN
compared/VBN
to/TO
the/DT
tissue/NN
biopsy/NN
suggest/VBP
that/IN
a/DT
higher/JJR
depth/NN
of/IN
sequencing/NN
coverage/NN
is/VBZ
required/VBN
for/IN
detection/NN
of/IN
genomic/JJ
alterations/NNS
in/IN
a/DT
liquid/JJ
biopsy/NN
than/IN
in/IN
a/DT
tissue/NN
biopsy/NN
./.
====================
PTEN/NN
frameshift/NN
mutation/NN
identified/VBD
in/IN
a/DT
breast/NN
tumor/NN
tissue/NN
and/CC
circulating/VBG
tumor/NN
DNA/NN
(/(
ctDNA/JJ
)/)
./.
====================
H259fs/NNS
mutation/NN
is/VBZ
detected/VBN
by/IN
the/DT
whole-exome/JJ
sequencing/NN
(/(
WES/NNS
)/)
(/(
A/NN
)/)
and/CC
OncoChase/NN
targeted/VBN
sequencing/NN
(/(
B/NN
)/)
in/IN
the/DT
breast/NN
tumor/NN
./.
====================
(/(
C/NN
)/)
The/DT
same/JJ
mutation/NN
is/VBZ
also/RB
detected/VBN
by/IN
the/DT
OncoChase/NN
targeted/VBN
sequencing/NN
in/IN
the/DT
ctDNA/JJ
./.
====================
(/(
D/NN
)/)
Validation/NN
of/IN
the/DT
PTEN/NN
mutation/NN
by/IN
a/DT
digital/JJ
polymerase/NN
chain/NN
reaction/NN
in/IN
ctDNA/JJ
./.
====================
In/IN
all/DT
experiments/NNS
,/,
the/DT
PTEN/NN
mutation/NN
was/VBD
not/RB
detected/VBN
in/IN
the/DT
matched/VBN
normal/JJ
DNA/NN
./.
====================
(/(
E/NN
)/)
Copy/NN
number/NN
alterations/NNS
identified/VBD
in/IN
breast/NN
tumor/NN
or/CC
ctDNA/JJ
by/IN
next/JJ
generation/NN
sequencing/NN
./.
====================
Amplification/NN
of/IN
FGFR1/NN
,/,
c-MYC/NN
,/,
CDK4/NN
,/,
and/CC
MDM2/NN
are/VBP
detected/VBN
in/IN
the/DT
tumor/NN
tissue/NN
by/IN
WES/NN
(/(
left/NN
panel/NN
)/)
./.
====================
Among/IN
them/PRP
,/,
c-MYC/NN
,/,
CDK4/NN
,/,
and/CC
MDM2/NN
amplifications/NNS
are/VBP
consistently/RB
detected/VBN
in/IN
the/DT
tumor/NN
tissue/NN
(/(
middle/JJ
panel/NN
)/)
or/CC
ctDNA/JJ
(/(
right/JJ
panel/NN
)/)
by/IN
OncoChase/NN
targeted/VBN
panel/NN
sequencing/NN
./.
====================
The/DT
x-axis/NN
represents/VBZ
genomic/JJ
position/NN
and/CC
the/DT
y-axis/NN
represents/VBZ
the/DT
relative/JJ
depth/NN
ratio/NN
(/(
tumor/matched/JJ
normal/JJ
)/)
in/IN
log2/NN
scale/NN
./.
====================
VAF/NN
,/,
variant/JJ
allele/NN
frequency/NN
./.
====================
